TLR2-IN-C29 is an inhibitor of TLR2/1 and TLR2/6 signaling.

E6446 is a novel and potent Toll-like receptor (TLR)7 inhibitor.

MD2-TLR4-IN-1 (compound 22m) is an inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex, inhibiting lipopolysaccharides (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with IC50 of 0.89 μM and 0.53 μM, respectively.

CU-CPT17e is a multi-TLR (Toll-like receptor) agonist that activates TLR3, TLR8, and TLR9 with immunomodulatory activities.

Loxoribine (7-Allyl-8-oxoguanosine; RWJ-21757) is a novel and potent immunostimulant agent acting as an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist.

Resatorvid (formerly also known as TAK-242) is a novel, cell-permeable and potent TLR4 (Toll-Like Receptor) signaling inhibitor with immunomodulatory and anti-inflammatory activity.

Poly:Kanamycin is a mixture of poly (I:C) and kanamycin.

Vesatolimod (formerly known as GS9620; GS-9620) is a novel potent, selective and orally bioactive small molecule agonist of Toll-like receptor 7 (TLR-7) with antiviral activity.

Gardiquimod trifluoroacetate (TFA), the TFA salt of Gardiquimod, is a TLR7 (toll-like receptor 7) agonist, also inhibit HIV-1 reverse transcriptase.

Gardiquimod, an imidazoquinoline compound, is a novel, potent and specific agonist of TLR7 (toll-like receptor 7) with antitumor and immunomodulatory effects.